tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Symbio Pharmaceuticals Faces Steep Decline in H1 FY2024

Symbio Pharmaceuticals Faces Steep Decline in H1 FY2024

Symbio Pharmaceuticals Limited (JP:4582) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Symbio Pharmaceuticals Limited reported a significant decline in financial performance for the first half of FY 2024, with net sales decreasing by 59.6% and a notable net loss attributable to owners of the parent. The company’s total assets have also seen a decrease from the previous fiscal year end. Despite these results, equity ratio remains stable at 85.0%, and no dividends have been paid or forecasted for FY 2024.

For further insights into JP:4582 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1